

UCSF

UC San Francisco Previously Published Works

Title

BCOR regulates myeloid cell proliferation and differentiation

Permalink

<https://escholarship.org/uc/item/3tc870nc>

Journal

Leukemia, 30(5)

ISSN

0887-6924

Authors

Cao, Q
Gearhart, MD
Gery, S
et al.

Publication Date

2016-05-01

DOI

10.1038/leu.2016.2

Peer reviewed



Published in final edited form as:

Leukemia. 2016 May ; 30(5): 1155–1165. doi:10.1038/leu.2016.2.

BCOR regulates myeloid cell proliferation and differentiation

Qi Cao^{1,*}, Micah D. Gearhart^{2,*}, Sigal Gery¹, Seyedmehdi Shojaee³, Henry Yang⁴, Haibo Sun¹, De-chen Lin¹, Jing-wen Bai^{5,1}, Monica Mead¹, Zhiqiang Zhao^{6,1}, Qi Chen⁷, Wen-wen Chien⁴, Serhan Alkan⁸, Tamara Alpermann⁹, Torsten Haferlach⁹, Markus Müschen³, Vivian J. Bardwell^{2,†}, and H. Phillip Koeffler^{1,4,10}

Qi Cao: Qi.Cao@cshs.org; Vivian J. Bardwell: bardw001@umn.edu

¹Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA

²Department of Genetics, Cell Biology and Development and Masonic Cancer Center, University of Minnesota, Minneapolis, MN

³Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA

⁴Cancer Science Institute of Singapore, National University of Singapore, Singapore

⁵Changjiang Scholar's Laboratory and Cancer Research Center, Shantou University Medical College, Shantou, China

⁶Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

⁷Department of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA

⁸Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA

⁹MLL Munich Leukemia Laboratory, Munich, Germany

¹⁰National University Cancer Institute of Singapore, National University Hospital, Singapore

Abstract

BCOR is a component of a variant Polycomb group repressive complex 1 (PRC1). Recently, we and others reported recurrent somatic *BCOR* loss-of-function mutations in myelodysplastic syndrome and acute myelogenous leukaemia (AML). However, the role of BCOR in normal hematopoiesis is largely unknown. Here, we explored the function of BCOR in myeloid cells using myeloid murine models with *Bcor* conditional loss-of-function or overexpression alleles. *Bcor* mutant bone marrow cells showed significantly higher proliferation and differentiation rates with upregulated expression of *Hox* genes. Mutation of *Bcor* reduced protein levels of RING1B, an H2A ubiquitin ligase subunit of PRC1 family complexes and reduced H2AK119ub upstream of upregulated *HoxA* genes. Global RNA expression profiling in murine cells and AML patient samples with *BCOR* loss-of-function mutation suggested that loss of *BCOR* expression is

*These authors contributed equally to this work

†Co-last author

CONFLICT OF INTEREST

The authors declare no competing financial interests.

associated with enhanced cell proliferation and myeloid differentiation. Our results strongly suggest that BCOR plays an indispensable role in hematopoiesis by inhibiting myeloid cell proliferation and differentiation and offer a mechanistic explanation for how BCOR regulates gene expression such as *Hox* genes.

INTRODUCTION

BCOR was originally identified via its interaction with the site-specific DNA binding transcription factor BCL6 whose aberrant expression drives formation of diffuse large B cell lymphomas (DLBCL).^{1,2} BCOR is likely to be a crucial mediator of BCL6 function in these cancers.³ By contrast, recurrent somatic *BCOR* mutations have been identified in human cancers including retinoblastoma, medulloblastoma, osteosarcoma, and hepatocellular carcinoma^{4–8} suggesting that BCOR can also function as a tumor suppressor protein. Using whole-exome sequencing, we and others have recently detected somatic *BCOR* mutations in acute myelogenous leukaemia with normal karyotypes (CN-AML, 3.8%), myelodysplastic syndrome (MDS, 4.2%), and chronic myelomonocytic leukemia (CMML, 7.4%) and found that these mutations are associated with a poor prognosis.^{9,10} Recent reports showed the presence of somatic mutations of *BCOR* in acquired aplastic anemia.^{11,12} However, knowledge of the role that BCOR plays in normal hematopoiesis is limited and its potential function as a tumor suppressor in hematopoietic transformation is largely unknown.

The X-linked *BCOR* gene is essential for human development.¹³ Female patients harboring heterozygous mutations in *BCOR* develop oculofaciocardiodental (OFCD) syndrome. Peripheral blood lymphocytes from OFCD patients show strongly biased inactivation of the X chromosome harboring the mutant *BCOR* allele,¹³ suggesting that BCOR is required for normal hematopoiesis. Furthermore in mice, BCOR appears to play a role in differentiation of primitive erythroid and lymphoid cells.¹⁴

BCOR is found in a multi-subunit complex with mammalian homologs of Polycomb-group (PcG) proteins.^{15–17} PcG genes were originally identified in *Drosophila melanogaster* as negative regulators of *Hox* genes.¹⁸ PcG protein homologs are involved in many biological processes in mammals, including maintenance of stem cell identity, differentiation and cancer development^{19–21} and are involved in various cellular functions including posttranslational histone modification and chromatin compaction.²² Polycomb Repressive Complex-1 (PRC1) and -2 (PRC2) are the two main PcG complexes, which catalyze repressive histone modifications: monoubiquitination of histone H2A at lysine-119 (H2AK119ub) and methylation of histone H3 at lysine-27 (H3K27me), respectively.^{20,23–25} At least six mammalian PRC1 complexes (PRC1.1-PRC1.6) have been identified that have different subunit compositions but all contain the RING1A/B catalytic subunit(s).¹⁷ BCOR is a component of the PRC1.1 complex that contains RING1A/B, PCGF1, RYBP/YAF2, SKP1 and KDM2B.^{16,17}

The biological and functional relevance of the diversity of PRC1 complexes is an active area of investigation. Analysis of loss- or gain-of-function alleles of components of the PRC1 complex can provide insights into specific roles of that complex. Here, we have taken this approach to investigate the role of BCOR and thus PRC1.1 in hematopoiesis. We report that

BCOR plays an important role in regulating hematopoietic cell proliferation and differentiation. BCOR is involved in maintaining RING1B protein abundance and regulates gene transcription through regulation of H2A ubiquitination. Our data indicate that BCOR provides an important link between transcriptional and epigenetic regulation that is required for myeloid cell proliferation and differentiation.

MATERIALS AND METHODS

Mice

The details of the generation of the *Bcor*^{FL/Y} allele will be described elsewhere (Hamline, Corcoran, Wamstad et al., in prep.). In brief, exons 9 and 10 of *Bcor* allele were flanked by LoxP sites to allow their removal via expression of Cre recombinase. Excision of these exons results in a frame shift and a premature stop codon causing nonsense mediated decay and/or carboxy-terminal deletion of the BCOR protein. The details of the generation of the *Rosa26*^{LsLmBcorA} allele will be described elsewhere (Hamline, Corcoran, Wamstad et al., in prep.). In brief, a conditional (Lox-Stop-Lox) myc-tagged *Bcor* splice version A (*mBcorA*) expression cassette was inserted into the murine Rosa26 locus (*Rosa26*^{LsLmBcorA}). *mBcorA* overexpression can be induced by Cre excision of the loxP-flanked Stop-cassette (LsL).

Cell culture, transfection and electroporation

Bcor^{FL/Y} BM cells were cultured in Iscove's Modified Dulbecco's Media (Invitrogen, Grand Island, NY,) with 20% fetal bovine serum (FBS) plus 50 ng/ml stem cell factor (SCF), 25 ng/ml IL6 and 10 ng/ml IL-3. HL60, NB4 and 293T cells (American Type Culture Collection, Manassas, VA) were cultured in RPMI-1640 medium plus 10% FBS. HL60 and NB4 cells were transfected either with non-targeted siRNA or siRNA against *BCOR* (Dharmacon, Grand Island, NY, 5'-GGACTAACATCACTGAAGA-3)³ using *Amaxa*TM NucleofectorTM Technology (Lonza, Iowa City, IA, USA), following the manufacturer's instructions. siGENOME siRNA smartpool targeting *HoxA5*, *HoxA7* and *HoxA9* (Dharmacon) were transfected into NIH3T3 cells (RNAimax, Invitrogen) as well as Control and *Bcor* Mutant cells (Amaxa Kit V, T-016 programme), following the manufacturer's instructions.

Retroviral constructs and transduction

Retroviral supernatants were produced by transfecting Platinum-E (Plat-E) cells with the retroviral constructs Cre-IRES-puro or Puro empty vector controls using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. At 24 and 48 hours post transfection, the virus supernatants were collected and put through a 0.45 µm filter. Virus were loaded by centrifugation (2,000g, 90 min at 32 °C) twice on 50 µg/ml RetroNectin- (Takara, Iowa City, IA, USA) coated non-tissue culture six-well plates. Two to three million cells were transduced per well by centrifugation at 500g for 30 min and maintained for 48 h at 37 °C with 5% CO2 before transferring into culture flasks. Transduced cells were selected with puromycin (3 µg/ml for 3 days).

Western blot and histone extraction

Cell lysate was separated on SDS-PAGE gel (Bio-Rad, Hercules, CA, USA) and transferred to nitrocellulose membranes. After incubation with appropriate primary and secondary antibodies, the immunoblots were developed using SuperSignal Western blotting kits (Pierce Biotechnology, Hercules, CA, USA) and exposed to X-ray film. The following antibodies were used: BCOR,¹⁶ RING1B (Cell Signaling Technology, Danvers, MA, USA, D22F2), ubiquitin H2AK119 (Millipore, Temecula, CA, USA 05-678), H2A (Cell Signaling Technology, #2578) and β -actin (Sigma, St. Louis, MO, USA A5316). Endogenous ubH2A analysis was carried out following methods exactly as previously described.²⁶

Chromatin immunoprecipitation

Assays were performed using MAGnify™ Chromatin Immunoprecipitation System (Invitrogen) according to the manufacturer's protocol. Briefly, cells were fixed by formaldehyde. For each ChIP reaction, 2×10^6 cells were used. All resulting precipitated DNA samples were quantified with Real-time PCR. Data were expressed as the percentage of input DNA. The primer sequences for *Bcor* and the ubiquitinated H2A-binding region of the *HoxA5*, *HoxA7* and *HoxA9* are indicated in Supplementary Table 1.

Reverse transcription reaction and quantitative PCR

Total RNA from cultured cells was extracted using RNeasy Mini Kit (Qiagen, St. Louis, MO, USA). Two hundred nanograms of RNA were processed directly to cDNA by reverse transcription with qScript cDNA SuperMix following the manufacturer's instructions (Quanta, St. Louis, MO, USA). Sequences for primers used in this study are listed in the Supplementary Table 1. We used SYBR Premix Ex Taq (Perfect Real-time; Takara Bio) for qPCR according to the manufacturer's instructions.

RNA microarray and data analysis

Total RNA from either mouse cells or AML patients' mononuclear cells was isolated by RNeasy (Qiagen, St. Louis, MO, USA) purification, checked for quality using an Agilent Bioanalyser (Agilent Technologies). RNA from murine cells was hybridized on Illumina Mouse WG-6 beadchips. Raw expression data were obtained from the GenomeStudio software with the subtraction of the background. Prior to identification of differentially expressed genes, raw data were normalized based on the Cross-Correlation method.²⁷ Significant changes in gene expression were identified based on the average fold change cutoff of 1.5, and the cutoff of the False Discovery Rate (FDR) -corrected p-value cross all replicates at 0.05.

Total RNA from human AML patient samples with either WT or mutant *BCOR* identified by whole-exome sequencing⁹ were hybridized on Affymetrix GeneChip HGU133 plus 2. The whole transcriptome gene-level expression data were obtained by using the Robust Multichip Average (RMA) method, which is publically available in the "affy" package of Bioconductor (<https://www.bioconductor.org>). Informed consent was obtained from all subjects and the study was approved by the ethics committee at Munich Leukemia Laboratory. All microarray data are available in the Gene Expression Omnibus (GEO, GSE69624).

For identification of enriched gene sets, Gene Set Enrichment Analysis (GSEA) was performed based on the normalized data and using GSEA v2.07 tool (<http://www.broad.mit.edu/gsea/>) with msigdb.v4.0.

Methylcellulose colony assay

BM cells were added to methylcellulose containing growth factors (Methocult 3434, containing IL-3, IL-6 and stem cell factor. Stem Cell Technology, Vancouver, Canada). The mixture was plated in triplicate cultures. Colonies were counted on days 6 and 12. For self-renewal experiments, the cells in the methylcellulose plate (mostly colonies) were diluted with PBS, counted and replated on fresh methylcellulose and colony formation was observed and counted. Replatings were performed on day 10 of soft-gel culture. All experiments were done in triplicate.

Statistical analyses

The Student's t-test (Unpaired t-test) was used to analyze statistical significance and normality tests were used to test the assumption of a normal distribution. GraphPad Prism software (La Jolla, CA, USA) was used for statistical calculations. Error was calculated using SD unless otherwise noted; *P < 0.05, **P < 0.01.

RESULTS

BCOR regulates myeloid cell proliferation

To determine the role of BCOR in myeloid cell proliferation and differentiation, we used both loss-of-function and over expression approaches. First, we took advantage of a mouse conditional *Bcor* allele, *Bcor^{Fl}* (Hamline, Corcoran, Wamstad et al., in prep. and see Methods for a brief description). We isolated bone marrow (BM) cells from *Bcor^{Fl/Y}* animals and cultured these cells under myeloid stem/progenitor conditions [stem cell factor (SCF), IL-3 and IL-6]. These *Bcor^{Fl/Y}* BM cells were transduced with either a control empty retrovirus (hereafter “control cells”) or a retrovirus expressing CRE recombinase to induce deletion of the floxed *Bcor* exons and generate the mutant allele (*Bcor^{-Y}*, hereafter “*Bcor* mutant cells”). This mutant allele in which exons 9 and 10 are missing generates a mRNA with a premature stop codon. The resulting truncated protein is missing the region required for interaction with the core PRC1 components^{16,28} and mimics the pathogenic mutations seen in OFCD patients.¹³ Transduced cells were selected with 3 µg/ml puromycin for 3 days and subjected to further analysis. PCR confirmed DNA deletion and Western blot showed the expression of the truncated BCOR (Figure 1a). In liquid culture, the *Bcor* mutant cells demonstrated higher proliferation rates than the control cells (Figure 1b). Further, a serial methylcellulose replating colony assay demonstrated enhanced plating and serial replating capacity of the *Bcor* mutant cells compared with control cells (Figure 1c).

To determine the effect of BCOR overexpression on myeloid cell growth, we used a different conditional allele (*Rosa26^{LsLmBcorA}*) in which *Bcor* overexpression can be induced by Cre excision of the loxP-flanked Stop-cassette (LsL) (Hamline, Corcoran, Wamstad et al., in prep. and see methods for a brief description). BM cells from homozygous *Rosa26^{LsLmBcorA}/Rosa26^{LsLmBcorA}* mice were cultured under myeloid stem/progenitor

conditions and infected with either a control or Cre expression retrovirus to induce *Bcor* overexpression (Figure 1d, left panel). Transduced cells were selected with 3 µg/ml puromycin for 3 days and subjected to further analysis. The *Bcor* overexpressing cells exhibited a profound decreased proliferative rate as measured in the methycellulose colony assay (Figure 1d). Together, these results suggest that BCOR negatively regulates cell proliferation.

BCOR helps control myeloid cell differentiation

To identify BCOR-regulated genes in myeloid cells, we used microarrays to compare global gene expression in control and *Bcor* mutant BM cells cultured for 7 days under myeloid stem/progenitor conditions. Over 1,200 genes were misregulated by greater than 2-fold ($p < 0.05$, Figure 2a). *Bcor* mutant cells showed a disproportionate upregulation of genes involved in myeloid cell differentiation (12 out of the top 20 upregulated genes, Figure 2a). Gene set enrichment analysis (GSEA) revealed the significantly enriched expression of genes involved in myeloid cell differentiation²⁹ (Figure 2b) and the target genes of CCAAT/enhancer binding proteins (C/EBPs)³⁰ (Figure 2c) in *Bcor* mutant cells. Confirmation of the microarray results used quantitative real-time PCR (qRT-PCR) on selected genes (Figure 2d). These changes in gene expression suggest that *Bcor* mutant cells have a propensity to differentiate. In agreement, FACS analysis showed that 16% of the *Bcor* mutant cells expressed cell surface proteins related to myeloid differentiation (CD11b and/or Gr-1 positive) compared to the control population (5%) (Figure 2e, left). Statistic analysis of FACS analysis in 3 batches of control or *Bcor* mutant myeloid cells showed *Bcor* mutation significantly stimulates myeloid cell differentiation (Figure 2e, right). *Bcor* mutant cells also formed more granulocyte (Figure 2f, left panel) and monocyte (right panel) colonies in methylcellulose in the presence of granulocyte colony stimulating factor (GCSF) and monocyte colony stimulating factor (MCSF), respectively. In vivo, deletion of *Bcor* within the hematopoietic cells using *Vav-iCre*,³¹ led to an increase in peripheral blood neutrophils (Figure 2g), but no significant changes occurred in RBC, platelet and lymphocyte levels in these mice (Supplementary, Figure 1).

BCOR is a repressor of *HoxA* genes in myeloid cells

PcG proteins are known repressors of *Hox* genes; and a recent study showed that polycomb group ring finger 1 (Pcgf1),³² a member of the BCOR/BCORL1 complex, was involved in *Hox* gene expression regulation. We hypothesized that BCOR may alter expression of *Hox*, and other PcG targets. *Hox* genes were highly enriched in *Bcor* mutant myeloid cells among the differentially expressed genes (Figure 2a) compared to control cells. We performed hierarchical cluster analysis of *Hox* genes present in differentially expressed gene sets and showed *HoxA5*, *HoxA7*, *HoxA9* and *HoxB4* have the greatest fold changes in *Bcor* mutant cells (Figure 3a). qRT-PCR confirmed that the expression level of *HoxA5*, *HoxA7*, *HoxA9* and *HoxB4* were up-regulated in *Bcor* mutant cells (Figure 3b), while *Bcor* overexpressing cells had lower levels of the same set of *Hox* genes (Figure 3c). GSEA among the differentially expressed genes (Figure 2a) in control and *Bcor* mutant myeloid cells revealed that the expression of *HoxA9* targets,^{33,34} proliferation-associated genes³⁵ and MYC target genes³⁶ were significantly enriched in cells with *Bcor* mutation (Figure 3d). To demonstrate the significance of *Hox* genes as target of BCOR, we knocked down *HoxA5*, *HoxA7* and

HoxA9 in control and *Bcor* mutant myeloid cells (Figure 3e) and examined cell proliferation by methylcellulose colony assay. As shown in Figure 3f, knocking down of *HoxA5*, *HoxA7* and *HoxA9* significantly decreased the clonal growth rate of *Bcor* mutant cells.

BCOR affects RING1B protein levels and H2A ubiquitylation at *HoxA* loci

BCOR is reported to associate with RING1B to form the PRC1.1 complex.^{16,17} Western blot showed that RING1B protein levels are much lower in *Bcor* mutant myeloid cells and in myeloid differentiated cells, compared to control cells, respectively (Figures 4a and b). In contrast, the level of *Ring1b* mRNA was unchanged (Figure 4c). Therefore, BCOR protein abundance is correlated with RING1B protein abundance. This suggests that loss of BCOR protein, via either differentiation of wild type cells or by genetic ablation in the progenitor population, can lead to a decrease in the RING1B protein abundance. Global levels of H2AK119ub were unchanged in the *Bcor* mutant cells (Figure 4e). However, ChIP-qPCR revealed that H2AK119ub levels at the promoters of *HoxA5*, *HoxA7* and *HoxA9* were significantly decreased in *Bcor* mutant cells (Figure 4f).

Silencing *BCOR* induces myeloid cell differentiation of HL60 and NB4 cells

To address further the role of BCOR in myeloid cell differentiation, we investigated if silencing *BCOR* (by siRNA) will affect cell differentiation in the human acute promyeloid leukemia cell lines, HL60 and NB4.^{37,38} *BCOR* knockdown was confirmed by qRT-PCR (Figure 5a, left) and Western blot (Figure 5a, right). Silencing of *BCOR* resulted in a dramatic increase in myeloid differentiation of HL60 and NB4 cells as measured by expression of CD11b (Figure 5b). All-*trans* retinoic acid (ATRA) was used as a positive control for inducing differentiation (Figure 5b). Since our results suggested that BCOR is implicated in suppressing myeloid cell differentiation, we compared its expression level in HL60 and NB4 cells induced to differentiate by ATRA and BM cells treated with or without GCSF, and found that *BCOR* RNA and protein levels were dramatically decreased upon cell differentiation (Figure 5c). In agreement with our finding that BCOR decreases during myeloid differentiation, in silico analysis of normal human hematopoietic cells (Gene Enrichment Profiler, HemaExplorer)^{39,40} showed that *BCOR* levels are very high in long-term hematopoietic stem cells (LT-HSC) and its levels decrease with myeloid differentiation towards monocytes and granulocytes (nearly no expression).

Gene expression changes in *Bcor* mutant CD34+ cells are consistent with increased proliferation

To investigate further the role of BCOR in early hematopoietic cells, we performed global gene expression profiling of CD34+ cells from control and *Bcor* mutant cells. A total of 130 genes were misregulated by greater than 2-fold ($p < 0.05$) (Figure 6a). Congruent with our proliferation and colony assay results (Figure 1), GSEA revealed that the expression of proliferation-associated genes⁴¹ and MYC up-regulated genes³⁶ were significantly enriched in *Bcor* mutant CD34+ cells (Figure 6b).

Comparison of RNA expression in AML and MDS patients samples either with or without BCOR mutations

Next, we investigated whether the results from our murine model are relevant to human MDS/AML with *BCOR* mutations. *BCOR* mutations occur in about 4% of chromosome normal (CN)-AML.⁹ We compared global gene expression in de novo CN-AML male samples which were negative for *NPM1*, *CEBPA*, *FLT3-ITD* and *MLL-PTD* mutations and contained either WT *BCOR* or nonsense mutant *BCOR* (6 samples, Figures 7a–c and Supplementary Table 2). GSEA revealed that the expression of genes associated with myeloid cell differentiation²⁹ were significantly enriched in *BCOR* mutant samples, compared with control *BCOR* WT samples (Figure 7a). On the other hand, genes associated with hematopoietic stem cells (HSC)⁴² were depressed in the *BCOR* mutant samples (Figure 7b). Genes upregulated in the *BCOR* mutant samples also showed significant enrichment with genes upregulated upon loss of *BMi1*⁴³, a component of the PRC1.4 complex suggesting some functional overlap between PRC1.1 and PRC1.4 in AML (Figure 7c). We collected 73 MDS patients BM samples having a normal karyotype either with or without a *BCOR* mutation (Supplementary Table 3). qRT-PCR analysis in those samples revealed that expression of *HOXA9* was upregulated significantly in MDS patients with *BCOR* loss of function mutations (Figure 7d). In addition, we analyzed global gene expression in GEO datasets of 12 *BCOR* wild-type CN-AML cases and 12 *BCOR* mutated CN-AML cases (GSE30442).⁹ Similar to our analysis of control and *Bcor* mutant murine myeloid cells (Figure 6) and our patient samples (Figure 7), GSEA of this dataset demonstrated that *BCOR* mutant samples were enriched for proliferation-associated genes and MYC target genes (Supplementary Figure 2). These findings strongly suggest that BCOR functions as a tumor suppressor in myeloid cells at least in part by affecting proliferation and self-renewal.

DISCUSSION

Mammalian hematopoiesis is a hierarchical process giving rise to all types of mature blood cells. Proliferation and differentiation are controlled by an interactive network of transcription factors and epigenetic regulators. The very earliest HSCs are fairly quiescent. More mature stem cells and committed progenitor cells have higher proliferation rates. Although numerous factors involved in blood cell development have been identified, our knowledge of the process remains incomplete. In the present report, we discovered a previously unknown role of BCOR in hematopoiesis. Our results strongly suggest that BCOR plays an important role in normal hematopoiesis by contributing to the regulation of myeloid cell proliferation and differentiation. Global microarray and qRT-PCR uncovered expression of numerous genes that were altered in the *Bcor* mutant cells, several of which are implicated in myeloid differentiation (e.g. *Cebpa* and *Cebpe*). Importantly, our results showed that BCOR is a repressor of *HoxA* cluster of genes (*HoxA5*, *HoxA7* and *HoxA9*) in myeloid cells (Figures 3b and c, Figure 4f). Knock-down of *HoxA5*, *HoxA7* and *HoxA9* significantly decreased the clonogenic growth of *Bcor* mutant and wild type cells (Figures 3e and f), demonstrating the *Hox* genes, as targets of BCOR, played an important role in mediating BCOR's function in regulating myeloid cell proliferation. Similarly, a recent study demonstrated that knock-down of *Pcgf1*, another PRC1.1 complex component, in Lin-HSC also upregulated the expression of *Hox* genes and enhanced hematopoietic cell

proliferation.³² Furthermore, overexpression of *HoxA4*, *HoxA9*, and *HoxA10* in Lin⁻ HSC cells increased their plating capacity in methylcellulose.⁴⁴ In vivo, overexpression of *HoxA9* and *HoxA10* increased the pool of HSCs and myeloid progenitor cells and leads to late onset leukemia.^{45,46} These findings demonstrate the important role of *Hox* genes in self-renewal of hematopoietic cells. Thus, up-regulation of *HoxA* genes upon *Bcor* loss, is likely responsible at least in part, for the extended clonogenic growth of *Bcor* mutant hematopoietic stem/progenitor cell (HSPC) in replating assays.

BCOR is a component of the PRC1.1 transcriptional repressive complex which also includes RING1A/B, YAF2/RYPB, PCGF1, and KDM2B.^{16,17} RING1B is the E3 ubiquitin ligase that functions as the catalytic core of PRC1 complexes and is responsible for monoubiquitylation of H2A at position 119 (H2AK119ub).^{23,24} H2A ubiquitination activity of the PRC1 complex is a crucial step to mediate PRC1-dependent repression of differentiation-related genes to maintain ES cell identity.⁴⁷ Since PcG proteins are known repressors of *Hox* genes, we hypothesized that loss of BCOR may disrupt the activity of the PRC1.1 complex and lead to upregulation of a subset of genes known to be repressed by PRC1 complex containing RING1B. Results showed that mutation of *Bcor* in murine myeloid cells was associated with a decrease in RING1B protein levels, while *Ring1b* mRNA levels remained unchanged. Western blot analysis showed that the global monoubiquitin level of H2AK119 was unchanged in the *Bcor* mutant cells. However, ChIP-qPCR revealed that H2AK119ub levels at the promoters of *HoxA5*, *HoxA7* and *HoxA9* were significantly decreased in *Bcor* mutant cells. These results offer a mechanistic explanation for how BCOR regulates gene expression in myeloid cells, wherein loss of BCOR is associated with the loss of ubH2A at specific promoters without altering global ubH2A levels. Up-regulation of *HOXA9* gene was also detected in MDS patient samples with *BCOR* loss of function mutations (Figure 7d).

MDS is a heterogeneous group of clonal BM disorders that predominate in the elderly. Often at the time of diagnosis, clonal expansion has replaced the normal hematopoietic cells. Unlike AML, MDS cells retain their ability to differentiate to mature myeloid blood cells, albeit often with various abnormalities.^{48,49} Thus, while the clonal population of MDS cells continues to expand in the BM, patients paradoxically experience variable cytopenias due to excessive cell death.⁵⁰ Loss of *BCOR* facilitates this phenotype by allowing an expanded marrow of hematopoietic cells at all stages of differentiation. Truncating mutations of BCOR are independently associated with a worse overall survival (OS) in MDS and a higher cumulative incidence of AML transformation.¹⁰ MDS can progress to AML which has a nearly complete block of differentiation. MDS cells with *BCOR* loss of function likely acquire additional mutations resulting in a block in differentiation. Interestingly in MDS and AML, *BCOR* mutations associate preferentially with a group of molecular aberrations including *RUNX1* and *DNMT3A* mutations.^{9,10} However, the exact role of BCOR in leukemia transformation awaits further studies.

In summary, our data suggest that BCOR plays an important role in normal hematopoiesis by contributing to the regulation of myeloid cell proliferation and differentiation. With loss of *Bcor* enhanced proliferation of more mature progenitor cells occurs allowing increased production of mature myeloid cells. Functionally, BCOR appears to play a critical role in

determining H2A ubiquitination levels and PcG proteins recruitment to promoters of lineage-specific genes to repress their expression. We hypothesize that loss of *BCOR* provides both a clonal growth advantage of the MDS clone, which when combined with additional mutations, can result in neoplastic transformation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dimitris Kioussis for sharing the *Vav-iCre* allele. This work was funded by the National Institutes of Health, USA (NIH; Grant No. R01CA026038-35 (HPK) and 5R01CA071540 (VJB)), the Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award to H. Phillip Koeffler and the NMRC Centre Grant awarded to National University Cancer Institute of Singapore, the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiatives. Further thanks is given to Reuben Yeroushalmi, Blanche and Steven Koegler. Additional funding came from the Minnesota Masonic Charities, the University of Minnesota OVPR and the Leukemia Research Fund (VJB).

References

- Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. *Genes Dev.* 2000; 14:1810–1823. [PubMed: 10898795]
- Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. *Cancer Cell.* 2005; 7:445–455. [PubMed: 15894265]
- Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. *Cell Rep.* 2013; 4:578–588. [PubMed: 23911289]
- Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature.* 2012; 481:329–334. [PubMed: 22237022]
- Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature.* 2012; 488:106–110. [PubMed: 22820256]
- Pierron G, Tirode F, Lucchesi C, Reynaud S, Ballet S, Cohen-Gogo S, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. *Nat Genet.* 2012; 44:461–466. [PubMed: 22387997]
- Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, et al. High-resolution characterization of a hepatocellular carcinoma genome. *Nat Genet.* 2011; 43:464–469. [PubMed: 21499249]
- Yamamoto Y, Abe A, Emi N. Clarifying the impact of polycomb complex component disruption in human cancers. *Mol Cancer Res.* 2014; 12:479–484. [PubMed: 24515802]
- Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood.* 2011; 118:6153–6163. [PubMed: 22012066]
- Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzac L, Okuno Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. *Blood.* 2013; 122:3169–3177. [PubMed: 24047651]
- Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. *Blood.* 2014; 124:2698–2704. [PubMed: 25139356]

12. Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, et al. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. *N Engl J Med*. 2015; 373:35–47. [PubMed: 26132940]
13. Ng D, Thakker N, Corcoran CM, Donnai D, Perveen R, Schneider A, et al. Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR. *Nat Genet*. 2004; 36:411–416. [PubMed: 15004558]
14. Wamstad JA, Corcoran CM, Keating AM, Bardwell VJ. Role of the transcriptional corepressor Bcor in embryonic stem cell differentiation and early embryonic development. *PLoS One*. 2008; 3:e2814. [PubMed: 18795143]
15. Sanchez C, Sanchez I, Demmers JA, Rodriguez P, Strouboulis J, Vidal M. Proteomics analysis of Ring1B/Rnf2 interactors identifies a novel complex with the Fbxl10/Jhdm1B histone demethylase and the Bcl6 interacting corepressor. *Mol Cell Proteomics*. 2007; 6:820–834. [PubMed: 17296600]
16. Gearhart MD, Corcoran CM, Wamstad JA, Bardwell VJ. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. *Mol Cell Biol*. 2006; 26:6880–6889. [PubMed: 16943429]
17. Gao Z, Zhang J, Bonasio R, Strino F, Sawai A, Parisi F, et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. *Mol Cell*. 2012; 45:344–356. [PubMed: 22325352]
18. Lewis EB. A gene complex controlling segmentation in *Drosophila*. *Nature*. 1978; 276:565–570. [PubMed: 103000]
19. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell*. 2008; 132:567–582. [PubMed: 18295576]
20. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. *Nature*. 2011; 469:343–349. [PubMed: 21248841]
21. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. *Nat Rev Cancer*. 2006; 6:846–856. [PubMed: 17060944]
22. Simon JA, Kingston RE. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. *Mol Cell*. 2013; 49:808–824. [PubMed: 23473600]
23. de Napoles M, Mermoud JE, Wakao R, Tang YA, Endoh M, Appanah R, et al. Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation. *Dev Cell*. 2004; 7:663–676. [PubMed: 15525528]
24. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of histone H2A ubiquitination in Polycomb silencing. *Nature*. 2004; 431:873–878. [PubMed: 15386022]
25. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. *Nat Rev Mol Cell Biol*. 2009; 10:697–708. [PubMed: 19738629]
26. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. *Mol Cell*. 2005; 20:845–854. [PubMed: 16359901]
27. Chua SW, Vijayakumar P, Nissom PM, Yam CY, Wong VV, Yang H. A novel normalization method for effective removal of systematic variation in microarray data. *Nucleic Acids Res*. 2006; 34:e38. [PubMed: 16528099]
28. Junco SE, Wang R, Gaipa JC, Taylor AB, Schirf V, Gearhart MD, et al. Structure of the polycomb group protein PCGF1 in complex with BCOR reveals basis for binding selectivity of PCGF homologs. *Structure*. 2013; 21:665–671. [PubMed: 23523425]
29. Brown AL, Wilkinson CR, Waterman SR, Kok CH, Salerno DG, Diakiw SM, et al. Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling. *J Leukoc Biol*. 2006; 80:433–447. [PubMed: 16769770]
30. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. *Blood*. 2005; 106:2827–2836. [PubMed: 15985538]
31. de Boer J, Williams A, Skavdis G, Harker N, Coles M, Tolaini M, et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. *Eur J Immunol*. 2003; 33:314–325. [PubMed: 12548562]

32. Ross K, Sedello AK, Todd GP, Paszkowski-Rogacz M, Bird AW, Ding L, et al. Polycomb group ring finger 1 cooperates with Runx1 in regulating differentiation and self-renewal of hematopoietic cells. *Blood*. 2012; 119:4152–4161. [PubMed: 22411870]
33. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. *Blood*. 2009; 113:2375–2385. [PubMed: 19056693]
34. Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A, et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. *Blood*. 2006; 108:297–304. [PubMed: 16507773]
35. Venezia TA, Merchant AA, Ramos CA, Whitehouse NL, Young AS, Shaw CA, et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. *PLoS Biol*. 2004; 2:e301. [PubMed: 15459755]
36. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. *Genome Biol*. 2003; 4:R69. [PubMed: 14519204]
37. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). *Blood*. 1991; 77:1080–1086. [PubMed: 1995093]
38. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. *Blood*. 1979; 54:713–733. [PubMed: 288488]
39. Benita Y, Cao Z, Giallourakis C, Li C, Gardet A, Xavier RJ. Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor. *Blood*. 2010; 115:5376–5384. [PubMed: 20410506]
40. Bagger FO, Rapin N, Theilgaard-Monch K, Kaczowski B, Thoren LA, Jendholm J, et al. HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. *Nucleic Acids Res*. 2013; 41:D1034–1039. [PubMed: 23143109]
41. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nat Genet*. 2008; 40:499–507. [PubMed: 18443585]
42. Jaatinen T, Hemmoranta H, Hautaniemi S, Niemi J, Nicorici D, Laine J, et al. Global gene expression profile of human cord blood-derived CD133+ cells. *Stem Cells*. 2006; 24:631–641. [PubMed: 16210406]
43. Douglas D, Hsu JH, Hung L, Cooper A, Abdueva D, van Doorninck J, et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. *Cancer Res*. 2008; 68:6507–6515. [PubMed: 18701473]
44. Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK. Leukemogenic transformation by HOXA cluster genes. *Blood*. 2010; 115:2910–2918. [PubMed: 20130239]
45. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. *Blood*. 2002; 99:121–129. [PubMed: 11756161]
46. Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. *Mol Cell Biol*. 1997; 17:495–505. [PubMed: 8972230]
47. Endoh M, Endo TA, Endoh T, Isono K, Sharif J, Ohara O, et al. Histone H2A mono-ubiquitination is a crucial step to mediate PRC1-dependent repression of developmental genes to maintain ES cell identity. *PLoS Genet*. 2012; 8:e1002774. [PubMed: 22844243]
48. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. *Blood*. 1993; 81:1580–1585. [PubMed: 8453104]
49. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. *Blood*. 1995; 86:268–276. [PubMed: 7795232]


50. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. *Nat Rev Cancer*. 2012; 12:849–859. [PubMed: 23175121]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Figure 1.**

BCOR regulates myeloid cell proliferation. **(a–c)** *Bcor^{Fl/Y}* BM cells cultured with SCF, IL-3 and IL-6 were transduced with either empty vector control or Cre expressing retrovirus to generate *Bcor^{Fl/Y}* control (Con) and *Bcor^{-Y}* mutant (Mut) cells. Transduced cells were selected with 3 μ g/ml puromycin for 3 days and then were subjected to studies. **(a)** Cre mediated deletion of *Bcor* exons 9 and 10 was confirmed by qRT-PCR with primers internal to the deletion (upper panel) and loss of full length BCOR with appearance of a truncated protein by Western blot (arrow, wild type BCOR; arrowhead, mut BCOR; lower panel). **(b)** Cell proliferation from Days 0 to 10 in liquid culture. Data are means $\pm$ SD of triplicate experiments. **(c)** Methycellulose colony replating assays (see Methods). **(d)** *Rosa26^{LSLmBcorA}* BM stem/progenitor cells were transduced with empty (EV) or Cre expressing lentivirus to generate the *Bcor* overexpression allele *Rosa26^{mBcorA}*. Left panel: *Bcor* overexpression was confirmed by Western blot and qPCR; Right panel: methycellulose colony assays. Data are means $\pm$ SD of triplicate experiments. * $P < 0.05$, ** $P < 0.01$ (two-tailed, Unpaired t test).






Figure 2. *Bcor* deletion in BM cells induces myeloid cell differentiation. **(a)** Heat map of genes with > 2 fold and $P < 0.05$ mRNA expression differences between *Bcor^{F/Y}* (Con) and *Bcor^{-/Y}* (Mut) myeloid cells cultured with IL-3, IL-6 and SCF. 850 genes were upregulated and 400 genes downregulated. The top 20 upregulated and the 10 most downregulated genes are named. * genes associated with mature myeloid development. **(b, c)** GSEA comparison of control and *Bcor* mutant myeloid cells for enrichment/depletion of genes up-regulated in myeloid cell differentiation **(b)** and CEBP's target genes **(c)**. The normalized enrichment scores (NES) and P values are indicated in each plot. **(d)** qRT-PCR analysis of the indicated genes. Relative mRNA amounts were normalized to *Gapdh*. Values are expressed as fold variation relative to control cells (Con); results are mean $\pm$ SD of three experiments. *Bcor* primers are primers internal to the deletion. **(e)** Representative FACS analysis of Gr-1 and CD11b in control and *Bcor* mutant cells cultured under myeloid stem/progenitor conditions (IL-3, IL-6 and SCF) is shown (left). Statistical analysis for Gr-1/CD11b FACS analysis of

three different batches of cells is shown (right). **(f)** Methycellulose colony assays for control and *Bcor* mutant cells with either GCSF (50 ng/ml) or MCSF (10 ng/ml). Colonies were counted on day 10 of culture. Values are expressed as colony numbers with means $\pm$ SD of three experiments. **(g)** *Bcor*^{F/FI} mice were crossed with *Vav-iCre* to delete *Bcor* in the hematopoietic lineages. Analysis of peripheral blood (HemaVet, Drew Scientific, Miami Lakes, FL, USA) of aged mice (~6–18 months) showed higher neutrophil levels in *Bcor*^{F/FI};*Vav-iCre* compared to *Bcor*^{F/FI} littermate controls. *P < 0.05; ** P < 0.01 (two-tailed, Unpaired t test).

**Figure 3.**

BCOR regulates *HoxA* cluster genes and silencing *HoxA* genes inhibits proliferation of *Bcor* mutant cells. (a) Hierarchical cluster analysis of *Hox* gene expression in *Bcor^{F/Y}* (Con) and *Bcor^{F/Y}* (Mut) myeloid cells revealed the up-regulation of several *Hox* genes with mutation of *Bcor*. (b, c) qRT-PCR analysis of the indicated *Hox* genes in either control or *Bcor* mutant cells (b) and in *Rosa26^{LmBcorA}* BM cells transduced with empty vector (EV) or Cre (producing *Bcor* overexpression) (c). Values are expressed as fold variation relative to control cells which was set to 100; results are mean $\pm$ SD of three experiments. * $P < 0.05$; ** $P < 0.01$ (two-tailed, Unpaired t test). (d) GSEA comparison of control and *Bcor* mutant myeloid cells for enrichment/depletion of indicated gene sets. The NES and P values are indicated in each plot. (e) *HoxA5*, 7 and 9 were knocked down by siRNA in NIH3T3 (gray bars), *Bcor^{F/Y}* (Con) and *Bcor^{F/Y}* (Mut) myeloid cells. Expression of *HoxA5*, 7 and 9 was checked by qPCR after siRNA transfection. Data are means $\pm$ SD of triplicate experiments. (f) Methycellulose colony assays for control and *Bcor* mutant myeloid cells either with or without *Hox* gene silencing. Colonies were counted on day 7 of culture. Values are

expressed as colony numbers with means $\pm$ SD of three experiments. * $P < 0.05$, ** $P < 0.01$ (two-tailed, Unpaired t test).

**Figure 4.**

Bcor mutation decreases RING1B levels and H2AK119ub at *HoxA* promoters. (a, e and f) *Bcor^{F/Y}* BM cells cultured with SCF, IL-3 and IL-6 were transduced with control or Cre expressing retrovirus to generate Con and Mut cells. Transduced cells were selected with 3 µg/ml puromycin for 3 days prior to studies. (a) *Bcor* deletion leads to decrease in RING1B protein levels. Western blot analysis of BCOR and RING1B in three pairs of control and *Bcor* mutant cells is shown (upper). Western blot was quantified by ImageJ software and relative full length BCOR and RING1B protein expression in each sample is shown (bottom). (b) BCOR and RING1B proteins are downregulated in BM cells with myeloid cell differentiation. BM cells from two WT mice (#1 and #2) were treated with 50 ng/ml GCSF

for 3 days to induce myeloid cell differentiation. BCOR and RING1B were examined by Western blot (upper). Quantification of Western blot is shown (bottom). (c) qPCR demonstrates no changes in the *Ring1b* mRNA level with BM cell differentiation induced by GCSF treatment. (d) BM cell differentiation induced by GCSF was confirmed by FACS using Gr-1 antibody. (e) Western blot analysis showing no change in global H2AK119 ubiquitination levels in *Bcor* mutant cells. β -actin or H2A was used as loading control for Western blot analysis. (f) Single-locus ChIP analysis using BCOR and H2AK119ub antibodies showing reduced H2A ubiquitination levels at the promoters of *HoxA5*, *HoxA7* and *HoxA9* in *Bcor* mutant cells. Results represent the mean $\pm$ three experiments. Data are means $\pm$ SD of triplicate experiments. * $P < 0.05$, ** $P < 0.01$ (two-tailed, Unpaired t test).




Figure 5. Silencing *BCOR* induces differentiation of HL60 and NB4 human myeloid leukemia cells. **(a)** Knockdown of *BCOR* by *siBCOR* confirmed by qRT-PCR (left) and Western blot (right) in NB4, HL60, and 293T cells. In qPCR, *BCOR* expression in cells transfected with siRNA against *BCOR* (*siBCOR*) was normalized to control (*siCon*) which was set to 100; results are mean $\pm$ SD of three experiments. **(b)** FACS of *CD11b* antibody 5 days after either *siCon* or *siBCOR* was transfected into HL60 and NB4 cells. ATRA (10^{-7} M, 5 days) treated HL60 and NB4 cells were used as positive controls for cell differentiation. **(c)** *BCOR* expression was compared by qRT-PCR (left) and Western blot (right) in BM, NB4 and HL60 cells that were either untreated (con) or induced to differentiate by incubation with 50 μ g/ml GCSF for 3 days (BM) or 10^{-7} M ATRA for 5 days (NB4 and HL60). * $P < 0.05$, ** $P < 0.01$ (two-tailed, Unpaired t test).




Figure 6. Gene expression changes in *Bcor* mutant CD34+ cells are consistent with increased proliferation. CD34+ control and CD34+ *Bcor* mutant murine cells were purified by sorting using flow cytometry. Gene expression analysis (Illumina MouseWG-6 beadchips) was performed in triplicate. (a) Heat map of genes with > 2 fold mRNA ($P < 0.05$) expression differences between CD34+ control and CD34+ *Bcor* mutant cells. 160 genes were upregulated and 70 genes were downregulated. Top 15 upregulated and 9 downregulated genes are named. (b) GSEA comparison of *Bcor* mutant and control cells for either enrichment or depletion of indicated enrichment gene sets. The NES and P value are indicated on each plot.




Figure 7.

BCOR loss of function mutations are associated with enhanced myeloid cell differentiation and dysfunction of PRC1 in MDS and AML cells of patients. (a–c) BM cells were collected from 6 male AML patients with WT *BCOR* (WT) and 6 male AML patients with *BCOR* nonsense mutation (Mut). Gene expression analysis (Affymatrix microarray) was performed, and GSEA comparison were made of Mut and WT cells for enrichment (left panels) or depletion (right panels) of up-regulated and down-regulated genes associated with myeloid cell differentiation (a), HSC (b), and PRC1 targets (c). The NES and P values are indicated in each plot. (d) qRT-PCR results for *HOXA9* expression from a total 73 MDS patients with normal karyotyping. BM cells were collected from 12 males with mutant *BCOR* (11 of which had destructive mutations), 26 males with wild type *BCOR*, 11 females with mutant *BCOR* (7 of which had destructive mutations) and 24 females with wild type *BCOR*.

Extracted RNA samples were subjected to qRT-PCR analysis. Each dot represents one sample and data represent mean $\pm$ SD with P values (two-tailed, Unpaired t test) indicated.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript